secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0001628280-23-006626
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Therapeutics files prospectus supplement for up to $204M in ATM sales
-----------------------------------------------------------------------------

- Remaining ATM capacity of $204.1M under $325M Sales Agreement with Jefferies LLC as of March 7, 2023.
- Filed Amendment No. 3 to the Open Market Sale Agreement to reflect the remaining shares.
- Filed legal opinion from Cooley LLP on validity of the common stock offered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023006626/0001628280-23-006626-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023006626/sgmo-20230307.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-006626

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer